For the first time in five years, new drugs have been added to the list of neurotoxic drugs originally compiled by Dr. Louis Weimer in 2007. The two new drugs are used in the treatment of cancer, while the other change involves a reclassification of antibacterial medications.
The first drug class is the fluoroquinolones, the most commonly prescribed of which is Ciprofloxacin, more commonly known simply as Cipro. Cipro is used to prevent infections that are proven, or strongly suspected, to be caused by bacteria. Before taking this drug, it is suggested that you tell your doctor about any nervous system problems, such as a peripheral neuropathy. It is frequently prescribed for urinary tract infections. The class will move up on the list from negligible or doubtful risk to causing uncertain or minor risk.
The next drug is ixabepilone, marketed with the trade name Ixempra. It is used in the treatment of metastic or locally advanced breast cancer and is given through an IV. The drug can cause decreased sensation, numbness and tingling in the hands and feet. Some patients have difficulty walking. The problems may continue as long as the therapy is continued. It is on the list under the heading, moderate to significant risk.
The final drug is Eribulin Mesylate, which is marketed under the name Halaven. It is advised that you tell your doctor if you have impaired blood circulation before beginning this treatment. It is a treatment for patients with breast cancer who have tried at least two other types of anti-cancer medicines. This treatment may cause numbness, tingling or burning in the hands and feet. Peripheral neuropathy is the most common side effect causing patients to discontinue taking Halaven. It appears on the neurotoxic drug list under the heading, moderate to significant risk.